Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.

Guillermo Garcia‐Manero, Aristoteles Giagounidis, Francisca Hernández et al.|Journal of Clinical Oncology|2024

Cited by 2